Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juyoung Hong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CRISPRi-Mediated Epigenetic Suppression of TERT Reduces Cell Growth in Non-Small-Cell Lung Cancer Cells

    by Seong-Ho Park, Juyoung Hong, Woochang Hwang, Minjeong Kim, Hyeon Jong Yu, Taegeun Bae, Hyomin K. Lee, Ji Yeoun Lee, Young Chan Lee, Chul-Kee Park, et al.

    TERT, the catalytic subunit of telomerase, is aberrantly activated in most cancers and represents an attractive therapeutic target. However, conventional TERT-targeting strategies, including chemical inhibitors and siRNA, are limited by several issues, such as insufficient efficacy and off-target effects. In this study, we investigated whether dCas9-KRAB-mediated CRISPR interference (CRISPRi) could overcome the limitations by transcriptional repression of TERT without DNA cleavage. We first assessed the efficacy of the dCas9-KRAB system by applying it to H1299 non-small-cell lung cancer cells and observed reduction in TERT expression up to approximately 80% and significant decreases in cell viability and growth. Transcriptome-wide analysis showed limited detectable changes in non-target-gene expression under the conditions tested. Together, the results suggest that dCas9-KRAB-mediated CRISPRi could serve as a proof-of-principle approach for targeted repression of TERT in cancer cells with limited detectable effects on non-target-gene expression.


  • Open Access

    Oxytocin Modulates Microglial IL-17-Linked Inflammatory Pathways Through the IL-6/COX-2

    by Woochang Hwang, Yong Hun Jang, Juyoung Hong, Suyeon Kang, Junho K. Hur, Hyun Ju Lee

    Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including interleukin-6, cyclooxygenase-2, and interleukin-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin pretreatment attenuates lipopolysaccharide-induced inflammatory priming in BV-2 microglial cells. BV-2 microglia were preincubated with oxytocin (33 ng/mL) for 2 h, followed by lipopolysaccharide (0.5 µg/mL) for 2 h. Expression of ionized calcium-binding adapter molecule 1, a microglia marker, in BV-2 cells was assessed by immunofluorescence. After lipopolysaccharide treatment, the gene expression of BV-2 cells was assayed at 1, 2, and 6 h post stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed. Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that oxytocin pretreatment attenuated lipopolysaccharide-induced transcriptional activation, including interleukin-6 and cyclooxygenase-2 upregulation. Pathway enrichment analyses suggested that oxytocin-responsive genes were linked to the interleukin-17 signaling pathway. Gene Ontology enrichment analysis showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Oxytocin pretreatment mitigates lipopolysaccharide-induced microglial activation by modulating the interleukin-17–interleukin-6/cyclooxygenase-2 axis, suggesting its potential role for oxytocin as an endogenous modulator of neuroinflammation during early brain development.


  • Open Access

    Oxytocin Modulates Microglial IL-17-Linked Inflammatory Pathways Through the IL-6/COX-2

    by Woochang Hwang, Yong Hun Jang, Juyoung Hong, Suyeon Kang, Junho K Hur, Hyun Ju Lee

    Background: Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including IL-6, COX-2, and IL-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin (OT) pretreatment attenuates lipopolysaccharide (LPS)-induced inflammatory priming in BV-2 microglial cells. Methods: BV-2 microglia were preincubated with OT (33ng/mL) for 2 hours, followed by LPS (0.5 µg/mL) for 2 hours. Expression of IBA1, a microglia marker, in BV-2 was assessed by immunofluorescence. After LPS treatment, the gene expression of BV-2 cells was assayed 2 and 6 hours post-LPS stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed with KEGG and GO analyses. Results: Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that OT pretreatment attenuated LPS-induced transcriptional activation, including IL-6 and COX-2 upregulation. KEGG pathway enrichment analyses suggested that OT-responsive genes were linked to the IL-17 signaling pathway. GO analyses showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Conclusions: OT pretreatment mitigates LPS-induced microglial activation by modulating the IL-17–IL-6/COX-2 axis, suggesting its potential role for OT as an endogenous modulator of neuroinflammation during early brain development.